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Abstract
Objective: Thrombolysis by recombinant tissue plasminogen activator (rt-PA)
is the main pharmacological therapy in acute ischemic stroke (IS); however, it
is only effective in a subset of patients. Here we aimed to investigate the role of
plasminogen activator inhibitor-1 (PAI-1), an effective inhibitor of t-PA, and
its major polymorphism (PAI-1 4G/5G) in therapy outcome. Methods: Study
population included 131 consecutive IS patients who all underwent thromboly-
sis. Blood samples were taken on admission, 1 and 24 h after rt-PA infusion.
PAI-1 activity and antigen levels were measured from all blood samples and the
PAI-1 4G/5G polymorphism was determined. Clinical data including NIHSS
were registered on admission and day 1. ASPECTS was assessed using CT
images taken before and 24 h after thrombolysis. Intracranial hemorrhage
(ICH) was classified according to ECASS II. Long-term outcome was defined
90 days post-event by the modified Rankin Scale (mRS). Results: PAI-1 activity
levels dropped transiently after thrombolysis, while PAI-1 antigen levels
remained unchanged. PAI-1 4G/5G polymorphism had no effect on PAI-1
levels and did not influence stroke severity. PAI-1 activity/antigen levels as mea-
sured on admission were significantly elevated in patients with worse 24 h
ASPECTS (<7). Logistic regression analysis including age, sex, NIHSS on
admission, BMI, history of arterial hypertension, and hyperlipidemia conferred
a significant, independent risk for developing ICH in the presence of 5G/5G
genotype (OR:4.75, 95%CI:1.18–19.06). PAI-1 levels and PAI-1 4G/5G poly-
morphism had no influence on long-term outcomes. Interpretation: PAI-1 5G/
5G genotype is associated with a significant risk for developing ICH in post-ly-
sis stroke patients.
Introduction
Ischemic stroke (IS) is a common vascular disease with
high morbidity and mortality.1 Although mechanical
thrombectomy has revolutionized stroke care in the past
decade,2 the most commonly used pharmacological ther-
apy of IS is still intravenous (i.v.) thrombolysis with
recombinant tissue plasminogen activator (rt-PA). With
the extended time window of 4.5 h,3 about half of the
patients receiving this therapy attain total or nearly total
neurological recovery at 3 months.4
Although the relative benefit of i.v. t-PA is unquestion-
able for selected patients with acute IS, unfortunately, in
a large proportion of patients neurological improvement
fails and about 6–8% develop hemorrhagic transforma-
tion after thrombolysis as a side effect.5 In order to
improve safety and outcome of i.v. rt-PA therapy, there is
a growing interest in finding new biomarkers as potential
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predictors of post-lysis intracranial bleeding and treat-
ment failure.
PAI-1 is a serine protease inhibitor that plays an essen-
tial role in the regulation of the fibrinolytic system. As
the most important inhibitor of t-PA, the relative balance
between PAI-1 and t-PA plays an important regulatory
role in fibrinolysis.6 Elevated PAI-1 levels have been long
identified as risk factor for cardiovascular disease and
stroke.6–8 Surprisingly, much less evidence is available on
changes in PAI-1 levels during thrombolysis in stroke
patients and its association with outcomes.
PAI-1 levels are regulated by a number of factors, for
example inflammation, obesity, circadian rhythm, and
genetic factors.6,9,10 Several polymorphisms within the
PAI-1 gene have been described to influence PAI-1 levels,
of which the most studied is the 675 4G/5G polymor-
phism of the promoter region (rs1799889). It has been
shown that both alleles of 4G/5G polymorphism contain
a binding site for a transcription activator, while the 5G
allele also contains a binding site for a transcription
repressor that partially overlaps with the activator-binding
site.11,12 Therefore, individuals with 4G/4G genotype have
the highest, while those with 5G/5G genotype have the
lowest circulating PAI-1 levels.13 An association between
the 4G/5G polymorphism and the risk of cardiovascular
or cerebrovascular disease has been described in observa-
tional studies, and a recent meta-analysis has indicated
that PAI-1 4G/5G polymorphism may serve as a genetic
biomarker for atherosclerotic diseases.14–16
To better understand the role of PAI-1 in the outcome
of stroke thrombolytic therapy, in the present study, we
measured PAI-1 activity and antigen levels during the
course of thrombolysis in a cohort of consecutive acute
ischemic stroke patients and studied the association of
PAI-1 levels and PAI-1 4G/5G polymorphism with the
outcome and safety of therapy.
Materials and Methods
Patients
Consecutive acute IS patients were enrolled in the study
at the Department of Neurology, University of Debrecen,
Hungary. Patient enrollment started in March 2011 and
lasted till December 2012. Inclusion and exclusion criteria
of patients included the standard criteria for rt-PA
administration of the 2008 ESO guideline.17 All patients
underwent thrombolysis within the 4.5 h therapeutic time
window using rt-PA according to standard protocols.17
As at the time of patient enrollment mechanical
thrombectomy was not yet available, none of the patients
received such treatment. Baseline characteristics of the
patient cohort have been published earlier.18 The presence
of IS was diagnosed based on clinical symptoms, brain
imaging using non-contrast computerized tomography
(NCCT) scan, and CT angiography (CTA). A control
NCCT was performed for every patient 24 h after the
event. Alberta Stroke Program Early CT Scores
(ASPECTS) were calculated at both NCCT examinations
by four independent radiologists.19 Stroke severity was
determined by NIHSS (National Institutes of Health
Stroke Scale) on admission, days 1 and 7 after therapy.20
Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
criteria was used to identify the etiology of stroke.21
Hemorrhagic transformation of stroke was classified as
symptomatic or asymptomatic intracranial hemor-
rhage (ICH) using the European Cooperative Acute
Stroke Study (ECASS) II criteria.22 Volume of post-lysis
intracerebral hemorrhage was calculated using 24h NCCT
scans as described previously.23 Short-term outcome was
assessed at day 1 after the thrombolysis. A decrease in
NIHSS score by at least 4 points or to 0 was defined as
favourable outcome, while an increase in NIHSS score by
at least 4 points was defined as poor outcome.24,25 Long-
term outcome was defined according to the modified
Rankin Scale (mRS) at 90 days. Patients with mRS 0–2
were defined as having favourable long-term outcome.26
Blood sampling and laboratory
measurements
Peripheral blood samples were taken before the initiation of
rt-PA infusion, immediately after the administration of rt-PA
infusion (e.g., approximately 1 h after the initiation of ther-
apy) and 24 h after thrombolysis. From the blood samples
taken on admission, routine laboratory examinations were
performed (ions, glucose levels, renal and liver function tests,
high-sensitivity C-reactive protein (hsCRP), complete blood
count) by standard methods (Roche Diagnostics, Mannheim,
Germany and Sysmex Europe GmbH, Hamburg, Germany).
Screening tests of coagulation (prothrombin time, activated
partial thromboplastin time and thrombin time) were per-
formed on a BCS coagulometer using routine methods (Sie-
mens Healthcare Diagnostic Products, Marburg, Germany).
For the examination of the PAI-1, blood samples were drawn
into Vacuette CTAD (sodium citrate, theophylline, adenosine,
and dipyridamole anticoagulation) tubes. Blood samples were
processed immediately and were centrifuged at 1220 g, room
temperature for 15 min. Plasma aliquots were labelled with a
code and stored at 70°C until further analysis. All measure-
ments were performed by investigators blinded to patient
identification and clinical data. PAI-1 activity and antigen
levels were measured using Technozym PAI-1 Actibind ELISA
and Technozym PAI-1 Antigen ELISA assays, respectively,
according to the manufacturer’s instructions. The Actibind
assay exclusively measures free, active PAI-1 (reference
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range: 1–7 U/mL as provided by the manufacturer). The
Technozym PAI-1 Antigen assay measures free, complexed,
and latent PAI (normal range: 7–43 ng/mL as provided by
the manufacturer). Other forms of PAI-1 or other plasmino-
gen activator inhibitors have no effect on the assays.
Genomic DNA was extracted from the buffy coat of
blood samples using standard methods (QIAamp DNA
Blood Mini Kit, Qiagen, Hilden, Germany). LightMixs
PAI-1 4G/5G kit was used to detect the 4G/5G polymor-
phism in the promoter region of PAI-1 using a Light-
Cycler 480 instrument (Roche Diagmostics GmbH,
Mannheim, Germany).
Statistical analysis
Statistical analysis was performed using Stata 12 (Stata
Corp, College Station, TX), the Statistical Package for
Social Sciences (SPSS, Release 22.0, Chicago, IL), and
GraphPad Prism 5.0 (GraphPad Prism Inc., La Jolla, CA).
Shapiro–Wilk test was used to assess the normality of the
data. Student’s t test or Mann–Whitney U test was per-
formed for two-group analyses. ANOVA with Bonferroni
post hoc test or Kruskal–Wallis analysis with Dunn–Bon-
ferroni post hoc test was applied for multiple compar-
isons. Pearson’s or Spearman’s correlation coefficient was
used to determine the strength of correlation between
PAI-1 levels and other continuous variables. Differences
between categorical variables were assessed by chi-squar-
edtest or Fisher’s exact test. Binary backward logistic
regression model was used to determine whether the pres-
ence of 5G/5G genotype is an independent predictor of
ICH after thrombolysis. Variables were selected for enter-
ing the multivariate model based on the results of uni-
variate analyses, correlation, and literature data. Results of
the logistic regression analysis were expressed as odds
ratio (OR) and 95% confidence interval (CI). A P-value
of <0.05 was considered statistically significant.
Informed consent
The Ethics Committee of the University of Debrecen,
Hungary approved the study. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki. All patients or their relatives provided written
informed consent.
Results
Baseline characteristics of enrolled patients
according to their PAI-1 4G/5G genotype
Baseline characteristics of enrolled patients are listed in
Table 1. Among the 131 patients enrolled, 31 subjects had
PAI-1 5G/5G genotype. Baseline clinical or laboratory
characteristics were not significantly different in PAI-1
5G/5G homozygotes versus PAI-1 4G carriers except for
significantly more post-lysis hemorrhagic events in PAI-1
5G/5G homozygotes (frequency of hemorrhage: 19.35%
vs. 7% in PAI 5G/5G homozygotes vs. PAI-1 4G carriers,
P = 0.036).
PAI-1 levels during thrombolysis
PAI-1 activity levels dropped transiently immediately after
thrombolysis (Fig. 1A). As compared to admission PAI-1
activity levels, a highly significant reduction was observed;
the median value of PAI-1 activity was below the lower
limit of the reference interval when measured immediately
after thrombolysis (PAI-1 activity on admission: median:
2.34, IQR: 1.46–5.17 U/mL; immediately after thromboly-
sis: median: 0.94, IQR: 0.73–1.18 U/mL). The narrow
interquartile range of PAI-1 activity level immediately
after thrombolysis is to be noted. Twenty-four hours after
thrombolysis PAI-1, activity showed a substantial eleva-
tion (median: 3.44, IQR: 1.65–7.60 U/L). As opposed to
PAI-1 activity, PAI-1 antigen levels remained unchanged
during the course of thrombolysis (Fig 1B). Best correla-
tion between PAI-1 activity and antigen levels was
observed 24 h after thrombolysis (Spearman r: 0.539,
P < 0.001; r: 0.355, P < 0.001, and r: 0.752, P < 0.001, on
admission, immediately after thrombolysis, and 24 h after
thrombolysis, respectively).
PAI-1 4G/5G polymorphism had no effect on PAI-1
activity and PAI-1 antigen levels as measured during the
course of thrombolysis in this cohort (Table S1). Among
the baseline clinical and laboratory parameters (e.g., age,
BMI, CRP, etc. as listed in Table 1), PAI-1 levels showed
a fair correlation with BMI and CRP, particularly in sam-
ples measured 24 h after thrombolysis (PAI-1 activity
24 h after thrombolysis and BMI: Spearman r: 0.338,
P < 0.001; PAI-1 activity 24 h after thrombolysis and
CRP: Spearman r: 0.418, P < 0.001). PAI-1 levels showed
insignificant diurnal variation in this patient cohort (me-
dian admission PAI-1 activity from 0:00 to 12:00 AM:
2.81, IQR: 1.48–5.97 U/mL vs. PAI-1 activity between
12:01–23:59: 2.09, IQR: 1.45–4.68 U/mL, P = 0.363).
Association of PAI-1 activity and antigen
levels with stroke severity, etiology, and
outcomes
PAI-1 activity and antigen levels on admission showed no
association with stroke severity or etiology (Table S2).
Admission and 24 h post-lysis, PAI-1 activity levels were
significantly higher in patients presenting with worse
ASPECTS (<7) at 24 h after thrombolysis (Table 2). PAI-
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Table 1. Baseline characteristics of enrolled patients according to their PAI-1 4G/5G genotype.
5G/5G 4G/5G and 4G/4G P
Number of patients 31 100
Age (years), mean (SD) 69.9 (13.6) 68.8 (11.8) 0.547
Male, n (%) 17 (54.8) 62 (62.0) 0.476
Cerebrovascular risk factors, n (%)
Arterial hypertension 26 (83.9) 74 (74.0) 0.259
Atrial fibrillation 7 (22.6) 28 (28.0) 0.551
Previous stroke 8 (26.7) 34 (34.3) 0.432
Hyperlipidemia 19 (61.3) 62 (62.0) 0.943
Diabetes mellitus 9 (29.0) 30 (30.0) 0.918
BMI 28.24 (4.80) 27.65 (5.07) 0.562
Smoking, n (%)
Non-smoker 17 (54.8) 52 (52.0)
Previous smoker 3 (9.7) 13 (13.0) 0.951
Current smoker 7 (22.6) 24 (24.0)
Undetermined 4 (12.9) 11(11.0)
Duration of thrombolysis, median (IQR) 60.0 (60.0–63.5) 60.0 (60.0-63.5) 0.444
Time-to-treatment (min), median (IQR) 158 (133–203) 153 (125–177) 0.231
rt-PA dose (mg), mean (SD) 69.5 (15.3) 67.7 (14.9) 0.732
Medication at enrollment, n (%)
Antihypertensive therapy 22 (75.9) 71 (71.7) 0.660
Antiplatelet drug 14 (45.2) 44 (44.9) 0.980
Anticoagulant drug 3 (10.0) 4 (4.04) 0.207
Lipid lowering therapy 9 (31.0) 29 (29.3) 0.857
Antidiabetic therapy 3 (10.0) 13 (13.3) 0.636
Laboratory measurements, median (IQR)
INR 0.98 (0.94–1.05) 0.99 (0.95–1.03) 0.905
APTT (sec) 28.6 (26.6–32.1) 28.35 (26.1–32.15) 0.920
WBC (G/L) 6.59 (5.76–8.66) 7.63 (6.24–9.06) 0.330
Platelets (G/L) 188 (169–253) 212 (171–255) 0.529
Serum glucose (mmol/L) 6.4 (5.7–8.7) 6.5 (5.5–7.4) 0.560
hsCRP (mg/L) 3.31 (1.50–6.63) 3.01 (1.70–5.42) 0.701
Creatinine (lmol/L) 67 (60–100) 81 (67–97) 0.180
Admission NIHSS, median (IQR) 9 (5–13) 8 (5–14) 0.693
Stroke etiology (TOAST), n (%)
Large-artery atherosclerosis 16 (51.6) 33 (33.0)
Small-vessel occlusion 3 (9.7) 10 (10.0) 0.292
Cardioembolic 5 (16.1) 22 (22.0)
Other/undetermined 7 (22.6) 35 (35.0)
Imaging data, n (%)
ASPECTS on admission
0–7 1 (3.8) 3 (4.5)
8–10 25 (96.2) 64 (95.5) 0.893
ASPECTS at 24 h after thrombolysis
0–7 10 (38.5) 28 (41.8)
8–10 16 (61.5) 39 (58.2) 0.769
Outcomes, n (%)
Short-term outcome (24 h)
Good outcome (4 points or 0) 10 (32.2) 28 (28.0)
Unchanged status (3 points) 9 (29.0) 49 (49.0) 0.496
Poor outcome (+4 points) 4 (12.9) 12 (12.0)
Undetermined 2 (6.5) 4 (4.0)
Long-term outcome (90 days)
mRS 0–2 9 (29.0) 48 (48.0)
mRS 3–6 15 (48.4) 36 (36.0) 0.176
Undetermined 7 (22.6) 16 (16.0)
(Continued)
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1 antigen levels were also significantly higher on admis-
sion and at 1 h post-lysis in those with worse ASPECTS
at 24 h (Table 2). Despite these associations, PAI-1 activ-
ity and antigen levels as measured during the course of
thrombolysis showed no association with post-lysis
hemorrhage, short-term or long-term functional out-
comes (Table 3 and Table 4). PAI-1 activity and antigen
levels at any given time point showed no correlation with
post-lysis intracerebral hematoma volume (data not
shown).
Table 1. Continued.
5G/5G 4G/5G and 4G/4G P
Intracranial hemorrhage (ECASS II)
No hemorrhage 25 (80.65) 93 (93)
aSICH 2 (6.45) 5 (5.0) 0.036
SICH 4 (12.9) 2 (2.0)
APTT, activated partial thromboplastin time; aSICH, asymptomatic intracerebral hemorrhage; ASPECTS, The Alberta Stroke Program early CT score;
ECASS II, European Co-operative Acute Stroke Study-II; hsCRP, high-sensitive CRP; INR, international normalized ratio; IQR, interquartile range;
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator; SD, standard devi-
ation; SICH, symptomatic intracerebral hemorrhage; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; WBC, white blood cell.
Figure 1. Plasminogen activator inhibitor-1 (PAI-1) activity (A) and antigen (B) levels as assessed on admission, immediately after thrombolysis,
and 24 h after thrombolysis in acute ischemic stroke patients. Solid symbols represent median values, whiskers indicate interquartile ranges.
Upper and lower limits of reference intervals are indicated by dotted lines. ***P < 0.0001 (Kruskal–Wallis analysis with Dunn–Bonferroni post hoc
test).
Table 2. PAI-1 activity and antigen levels according to ASPECTS on admission and at 24 h after thrombolysis.
ASPECTS on admission ASPECTS 24 h after thrombolysis
10-8 (n = 89) 7-0 (n = 4) P 10-8 (n = 55) 7-0 (n = 38) P
PAI-1 activity (U/mL), median (IQR)
On admission 2.44 (1.45–4.72) 4.78 (2.30–14.46) 0.262 1.91 (1.38–3.79) 3.43 (1.79–6.76) 0.038
1 h after thrombolysis 0.92 (0.72–1.14) 1.61 (0.59–3.70) 0.693 0.90 (0.69–1.13) 0.98 (0.72–1.25) 0.233
24 h after thrombolysis 3.80 (1.82–7.85) 3.42 (2.84–7.25) 0.856 2.94 (1.80–6.00) 5.17 (2.19–10.97) 0.084
PAI-1 antigen (ng/mL), median IQR
On admission 12.05 (4.03–23.92) 15.50 (7.09–39.66) 0.640 7.33 (3.99–20.24) 14.08 (7.61–26.31) 0.041
1 h after thrombolysis 11.12 (5.52–28.16) 12.22 (4.6–31.43) 0.802 9.53 (3.99–18.91) 19.23 (6.15–43.63) 0.023
24 h after thrombolysis 12.09 (3.99–26.26) 4.46 (3.99–8.51) 0.169 8.48 (3.99–19.96) 12.77 (3.99–34.11) 0.291
ASPECTS, The Alberta Stroke Program early CT score; IQR, interquartile range; PAI-1, plasminogen activator inhibitor 1.
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PAI-1 4G/5G genotype is an independent
predictor of ICH
Patients who suffered post-lysis ICH (n = 13) in this
cohort had significantly lower BMI (Table 5). The fre-
quency of hypertension and hyperlipidemia was signifi-
cantly lower in this group as compared to those without
post-lysis bleeding complications. In a binary backward
logistic regression model including age, gender, BMI,
NIHSS on admission, hypertension, hyperlipidemia and
PAI-1 4G/5G genotype, PAI-1 5G/5G genotype was
revealed as a significant, independent risk factor for post-
lysis ICH (Table 6). The risk conferred by PAI-1 5G/5G
for post-lysis ICH was almost fivefold (OR: 4.75, 95%CI:
1.18–19.06, P = 0.028). Patients with PAI-1 5G/5G geno-
type showed a trend toward larger post-lysis intracerebral
hemorrhage volume as compared to PAI-1 4G carriers
(median: 16.82, IQR: 1.46–58.16 cm3 vs. median: 0.67,
IQR: 0.26–13.55 cm3, P = 0.09; Fig. 2).
Discussion
Despite the fact that PAI-1 is the most effective natural
inhibitor of t-PA, to date, its role in the outcome of
ischemic stroke thrombolytic therapy has not been fully
elucidated.27 A major finding of this study is that PAI-1
Table 3. PAI-1 activity levels according to thrombolysis safety and outcomes.
PAI-1 activity (U/mL), median (IQR)
On admission P 1 h after thrombolysis P 24 h after thrombolysis P
Intracranial hemorrhage (ECASS II)
No hemorrhage 2.47 (1.48–5.17) 0.92 (0.73–1.16) 3.44 (1.71–7.66)
aSICH 1.73 (1.26–14.23) 0.667 1.04 (0.94–1.25) 0.210 1.57 (0.9–7.54)
SICH 2.19 (0.88–3.24) 1.02 (0.97–1.62) 6.26 (3.24–13.08) 0.345
Short-term outcome (24 h)
Good outcome ( 4 points or 0) 2.74 (1.59–6.82) 1.04 (0.77–1.15) 3.80 (2.23–7.27)
Unchanged status (3 points) 2.44 (1.45–4.47) 0.88 (0.65–1.2) 2.96 (1.58–7.54)
Poor outcome (+4 points) 2.04 (1.47–5.15) 0.730 0.97 (0.87–1.08) 0.364 5.21 (1.52–12.31) 0.326
Undetermined 1.31 (1.44–4.72) 0.96 (0.8–1.24) 1.52 (1.16–1.82)
Functional outcome at 90 days
mRS 0–2 2.47 (1.64–3.94) 0.90 (0.73–1.14) 2.86 (1.54–5.78)
mRS 3–6 2.13 (1.31–5.97) 0.845 0.98 (0.80–1.21) 0.478 4.84 (1.66–11.44) 0.091
Undetermined 2.44 (1.26–5.19) 1.08 (0.65–1.36) 4.20 (2.97–7.29)
aSICH, asymptomatic intracerebral hemorrhage; ECASS II, European Co-operative Acute Stroke Study-II; IQR, interquartile range, mRS, modified
Rankin Scale; PAI-1, plasminogen activator inhibitor 1; SICH, symptomatic intracerebral hemorrhage
Table 4. PAI-1 antigen levels according to thrombolysis safety and outcomes.
PAI-1 antigen (ng/mL), median (IQR)
On admission P 1 h after thrombolysis P 24 h after thrombolysis P
Intracranial hemorrhage (ECASS II)
No hemorrhage 12.00 (3.99–23.23) 11.73 (5.31–29.99) 9.51 (3.99–21.36)
aSICH 10.54 (4.03–17.04) 0.763 9.25 (3.99–22.05) 0.935 5.51 (3.99–23.83) 0.615
SICH 12.00 (3.99–23.23) 10.22 (6.60–18.45) 5.76 (0–52.57)
Short-term outcome (24 h)
Good outcome (4 points or 0) 18.13 (4.95–28.67) 12.31 (5.16–22.65) 8.34 (3.99–20.10)
Unchanged status (3 points) 10.46 (3.99–17.71) 9.87 (3.99–34.78) 9.51 (3.99–28.92)
Poor outcome (+4 points) 12.00 (3.99–24.39) 0.471 9.74 (6.15–18.94) 0.816 11.59 (3.99–19.96) 0.713
Undetermined 9.42 (5.88–15.11) 18.24 (10.75–37.42) 4.01 (3.99–8.06)
Functional outcome at 90 days
mRS 0–2 7.24 (3.99–19.96) 9.93 (3.99–21.46) 7.38 (3.99–19.75)
mRS 3–6 12.73 (4.03–23.92) 0.441 14.69 (5.87–35.47) 0.398 12.58 (3.99–36.03) 0.431
Undetermined 13.09 (5.68–25.48) 12.61 (5.66–37.69) 10.56 (3.99–12.56)
aSICH, asymptomatic intracerebral hemorrhage; ECASS II, European Co-operative Acute Stroke Study-II; IQR, interquartile range, mRS, modified
Rankin Scale; PAI-1, plasminogen activator inhibitor 1; SICH, symptomatic intracerebral hemorrhage.
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5G/5G genotype confers an independent, significant risk
for post-lysis ICH. In a most recent systematic review on
potential prognostic coagulation biomarkers in acute
ischemic stroke, PAI-1 was mentioned as one of the most
promising candidates when assessed before the start of
reperfusion treatment.27 Interestingly, to date, no study
Table 5. Characteristics of enrolled patients according to the presence of hemorrhagic transformation after thrombolysis.
No intracranial hemorrhage Intracranial hemorrhage P
Number of patients 118 13
Age (years), mean (SD) 70 (69.5) 64 (64.7) 0.548
Male n% 71 (60.2) 8 (61.5) 0.924
Cerebrovascular risk factors
Arterial hypertension 94 (79.7) 6 (46.2) 0.007
Atrial fibrillation 31 (26.3) 4 (30.8) 0.746
Previous stroke 42 (36.2) 0 (0) –
Hyperlipidemia 78 (66.1) 3 (23.1) 0.005
Diabetes mellitus 38 (32.2) 1 (7.7) 0.107
BMI 28.12 (5.02) 24.97 (3.82) 0.031
Smoking n%
Non-smoker 63 (53.4) 6 (46.2)
Previous smoker 14 (11.9) 2 (15.4) 0.358
Current smoker 26 (22.0) 5 (38.5)
Undetermined 15 (12.7) 0 (0)
Duration of thrombolysis, median (IQR) 60 (60–65) 60 (60–61.5) 0.444
Time-to-treatment (min), median (IQR) 155 (125–180) 144 (132–177) 0.231
rt-PA dose (mg), mean (SD) 69 (68.6) 65 (63.5) 0.732
Baseline NIHSS 8 (5–14) 12 (8–16) 0.189
Medication at enrollment, n (%)
Antihypertensive therapy 87 (75.7) 6 (46.2) 0.024
Antiplatelet drug 54 (46.6) 4 (30.8) 0.381
Anticoagulant drug 6 (5.2) 1 (7.7) 0.533
Lipid lowering therapy 37 (32.2) 1 (7.7) 0.106
Antidiabetic therapy 13 (11) 0 (0) 0.151
Stroke etiology (TOAST), n%
Large-artery atherosclerosis 43 (36.4) 6 (46.2)
Small-vessel occlusion 11 (9.3) 2 (15.4) 0.155
Cardioembolic 23 (19.5) 4 (30.8)
Other/undetermined 41 (34.8) 1 (7.7)
Basic laboratory measurements, median (IQR)
INR 0.98 (0.94–1.02) 1.07 (0.95–1.09) 0.905
APTT (sec) 28.4 (26–32.1) 28.6 (28.1–32.4) 0.920
WBC (G/L) 7.42 (6.08–8.61) 8.08 (6.49–9.41) 0.331
Platelets (G/L) 208 (171–254) 194 (169–260) 0.530
Serum glucose (mmol/l) 6.45 (5.5–7.95) 6.5 (5.9–7.4) 0.560
hsCRP (mg/L) 3.02 (1.7–5.8) 3.25 (1.6–6.6) 0.701
Creatinine (umol/L) 82.5 (65–98) 66 (57–71) 0.181
PAI-1 measurements
PAI-1 activity (U/mL), median (IQR)
on admission 2.47 (1.48–5.17) 1.91 (1.26–3.24) 0.507
immediately after thrombolysis 0.92 (0.73–1.16) 1.03 (0.97–1.25) 0.843
24 h after thrombolysis 9.51 (3.99–21.36) 5.51 (3.99–23.83) 0.274
PAI-1 antigen (ng/mL), median (IQR)
on admission 12 (3.99–23.23) 11.48 (6.44–18.52) 0.370
immediately after thrombolysis 11.73 (5.31–29.99) 9.74 (5.35–19.66) 0.752
24 h after thrombolysis 9.51 (3.99–21.36) 5.51 (3.99–23.83) 0.274
PAI-1 5G homozygous, n (%) 25 (21.19) 6 (46.15) 0.044
APTT, activated partial thromboplastin time; hsCRP, high-sensitive CRP; INR, international normalized ratio; IQR, interquartile range, PAI-1, plas-
minogen activator inhibitor 1; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation; TOAST, Trial of ORG 10172 in Acute
Stroke Treatment; WBC white blood cell.
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has been published where levels of PAI-1 during throm-
bolysis and PAI-1 4G/5G polymorphism were simultane-
ously investigated exploring potential associations with
the safety and outcome of stroke thrombolysis in humans.
Here we show that in this studied patient cohort, 46.15%
of patients suffering post-lysis ICH were PAI-1 5G
homozygous individuals. In a multiple logistic regression
model including all potential conventional risk factors for
post-lysis hemorrhage, the presence of PAI-1 5G/5G
genotype conferred the strongest independent risk for
hemorrhagic transformation (OR: 4.75 95%CI: 1.18–
19.06, P = 0.028). Moreover, a trend toward larger hema-
tomas in patients with PAI-1 5G/5G genotype was
observed, which further supports the potential role of this
polymorphism in the pathophysiology of post-lysis hem-
orrhage.
The contributing effect of PAI-1 5G/5G genotype to
post-lysis hemorrhage might be in theory related to its
effect on plasma PAI-1 levels regulating intravascular fib-
rinolysis or to a local effect of PAI-1 levels in the brain
parenchyma limiting excessive t-PA activity. To date,
published studies on plasma PAI-1 levels before or during
thrombolysis have included relatively few patients, and in
these studies either PAI-1 activity or antigen levels were
determined; thus results are difficult to compare, and are
often inconclusive or contradictory.28–31 Interestingly, in
our study PAI-1 4G/5G polymorphism did not seem to
have a major influence on plasma PAI-1 levels, which is
in line with few previous reports.32–35 The contributing
effect of PAI-1 5G/5G genotype to post-lysis ICH via
lower levels of PAI-1 at the site of the intracerebral lesion
is nevertheless biologically plausible. Local PAI-1 levels in
the thrombus might be essentially different from periph-
eral levels. Moreover, following acute stroke intravascular
PAI-1 levels show a rising tendency in animal models,36
and the same phenomenon was confirmed by this study
in humans. Known influencing factors of PAI-1 levels
(e.g., BMI and inflammation) were confirmed by the pre-
sent study. Interestingly, patients who suffered post-lysis
ICH were found to have significantly lower BMI.
Although a potential association between low PAI-1
levels, low BMI, and post-lysis hemorrhage is intriguing,
according to the backward regression model used in this
study, BMI was not conferred as an independent risk for
post-lysis hemorrhage and thus this line of investigations
should be carried out in larger patient cohorts.
The association of PAI-1 5G/5G genotype with post-ly-
sis intracerebral bleeding might extend beyond intravascu-
lar fibrinolysis. PAI-1, derived from astrocytes, can reduce
toxicity and neuronal cell damage by limiting excessive t-
PA activity in the brain parenchyma.37–39 Besides astro-
cytes, brain endothelial cells and pericytes also express
PAI-1.40 PAI-1 released from brain endothelial cells and
pericytes is known to prevent blood–brain barrier disrup-
tion.41 As PAI-1 4G/5G polymorphism affects PAI-1 tran-
scriptional activity in human astrocytes,42 the potential
contributing effect of PAI-1 5G/5G genotype to post-lysis
hemorrhage might be related to a direct, local exacerba-
tion of brain damage rather than a regulating effect on
plasma PAI-1 levels. Given the complex role of PAI-1 in
stroke pathophysiology, both theories are plausible and
warrant further experimental studies.
Here we also show that PAI-1 activity significantly
decreases upon thrombolytic treatment, while at the same
time no change is observed in PAI-1 antigen levels (in-
cluding free, t-PA-complexed, and latent forms). In this
cohort, median PAI-1 activity immediately after throm-
bolysis decreased below the lower limit of reference,
which indicates that PAI-1 efficiently inhibits excess rt-PA
during thrombolytic therapy. Nevertheless, absolute values
of PAI-1 activity and PAI-1 antigen did not show a signif-
icant association with the inefficacy or the safety of the
treatment. It must be noted, however, that significantly
higher on admission and 1h post-lysis PAI-1 antigen
Figure 2. Volume of post-lysis cerebral hemorrhage according to PAI-
1 4G/5G polymorphism in acute ischemic stroke patients. Box-
whiskers plots indicate median, interquartile range, and total range.
Six patients are included in both groups. Volume of hematoma was
not calculated in case of one patient who suffered subarachnoideal
hemorrhage.
Table 6. Independent predictors of post-lysis intracranial hemorrhage
in the studied cohort.
OR 95% CI P
BMI 0.89 0.77–1.04 0.149
Arterial hypertension 0.28 0.71–1.12 0.073
Hyperlipidemia 0.21 0.05–0.88 0.033
PAI-1 5G/5G genotype 4.75 1.18–19.06 0.028
Backward multiple regression model included age, sex, NIHSS on
admission, BMI, history of arterial hypertension, history of hyperlipi-
demia, PAI-1 5G/5G genotype. OR, odds ratio; CI, confidence interval;
BMI, body mass index; PAI-1, plasminogen activator inhibitor 1.
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levels were detected in patients in whom imaging data
suggested a more severe lesion at 24 h post-event
(ASPECTS < 7). In this group of patients with 24 h
ASPECTS of less than 7, median PAI-1 antigen levels on
admission and at 1h post-lysis were twice as high as com-
pared to those with better scores. A similar, significant
difference in PAI-1 activity levels on admission was
observed between the two groups of different stroke
severity as judged by imaging scores. These results indi-
cate that an elevated PAI-1 activity/antigen result on
admission might predict the possibility of a more severe
definitive lesion as detected by CT scans at 24 h post-
event. Such association of PAI-levels with imaging results
has not been shown before. Interestingly, the median
value of PAI-1 activity at 24 h post-lysis showed a clear
trend for increase in patients with worse long-term func-
tional outcomes (mRS 3–6); however, the association did
not reach statistical significance in this patient cohort
(P = 0.091).
Limitations
Similar to most observational clinical studies, our study
has limitations as well. The sample size is limited; how-
ever, as compared to other published studies measuring
fibrinolysis inhibitors in stroke patients on admission or
particularly at multiple time points during the course of
thrombolysis, it is the largest study as yet.28–31 Due to the
limited number of patients with post-lysis ICH, despite
the significant associations found, results presented here
must be confirmed and validated by larger studies.
Although the difference was nonsignificant, it must be
noted that large-artery atherosclerosis was more frequent
among PAI-1 5G/5G patients, that could have reached
statistical significance with a larger sample size. Moreover,
large-artery atherosclerosis and cardioembolic type of
strokes were more frequent in patients experiencing post-
lysis bleeding. Being single-centered, our study had the
advantages of uniform sample handling and uniform
patient care, but, as the center recruits patients from a
relatively large geographic area, unfortunately a propor-
tion of patients (23/131, 17.5%) were lost to long-term
follow-up. This percentage of follow-up drop-out is com-
parable to that observed in other studies involving post-
stroke patients;27 however, it might have influenced the
results regarding long-term outcomes to a certain extent
and thus larger clinical studies are needed to confirm our
data.
Conclusions
Here we demonstrate that PAI-1 5G/5G genotype is asso-
ciated with a significant, independent risk for developing
ICH in post-lysis stroke patients. Further studies are war-
ranted to validate this finding and to find out whether
patients with PAI-1 5G/5G genotype might benefit from
alternative therapeutic strategies.
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